Effect of ursodeoxycholic acid treatment on ileal absorption of bile acids in man as determined by the SeHCAT test

S Eusufzai, S Ericsson, T Cederlund, K Einarsson, B Angelin

Abstract
The effects of ursodeoxycholic acid on ileal absorption of bile acids and on serum bile acid and lipoprotein concentrations were studied. Eight healthy subjects were investigated. The \( \gamma \) emitting bile acid analogue, SeHCAT, was given orally and its fractional catabolic rate and seven day retention were assessed by repeated external counting over the upper abdomen during the next seven days. Ursodeoxycholic acid was then given orally at a dose of 15 mg/kg/day for three weeks and the study was repeated during treatment. The fractional catabolic rate increased by 64% (mean (SD), 0.333 (0.159) \( \vee \) 0.203 (0.061)/day; \( p<0.05 \) and seven day retention decreased by 44% (15 (10)) \( \vee \) 27 (10)\%, \( p<0.001 \), indicating bile acid malabsorption. Total serum cholesterol fell from 5.79 (1.22) to 5.50 (1.18) mmol/l (\( p=0.05 \), while serum ursodeoxycholic acid increased 22 fold (7.87 \( \vee \) 0.34 (0.24) \( \mu \)mol/l, \( p<0.001 \). Five of the subjects continued taking 30 mg/kg/day of ursodeoxycholic acid for one week and showed an increase in fractional catabolic rate of 81% (0.300 (0.091) \( \vee \) 0.166 (0.037)/day; \( p<0.05 \) and a fall in seven day retention of 50% (16 (12)) \( \vee \) 32 (8)\%, \( p<0.01 \). There were significant reductions in total cholesterol (5.36 (1.71) \( \vee \) 6.08 (1.47) mmol/l; \( p<0.05 \) and low density lipoprotein cholesterol (3.70 (1.33) \( \vee \) 4.58 (1.16) mmol/l; \( p<0.05 \). The results support the concept that ursodeoxycholic acid treatment interferes with the absorption of endogenous bile acids, and emphasise the beneficial effects of this treatment on lipoprotein concentrations in man.

The primary bile acids, cholic acid and chenodeoxycholic acid, are formed from cholesterol in the liver and stored in the gall bladder in the fasting state. 1 In response to a meal, bile acids are excreted into the intestine where they contribute to the efficient absorption of dietary fat and cholesterol. The secondary bile acids, deoxycholic acid and lithocholic acid, are the result of dehydroxylation of cholic acid and chenodeoxycholic acid by intestinal bacteria. The reabsorption of bile acids is very efficient, particularly because of active uptake in the distal ileum. The synthesis of bile acids is regulated by a homeostatic mechanism in which bile acids returning to the liver from the intestine inhibit their own synthesis. 2 The demand for hepatic cholesterol increases where bile acid synthesis is stimulated, and this is met by an increased cholesterol synthesis as well as by an increased expression of the low density lipoprotein receptors. 3 Thus, disturbances in bile acid kinetics may influence low density lipoprotein catabolism in several clinical situations.

Ursodeoxycholic acid, which is the 7\( \beta \) epimer of chenodeoxycholic acid, is a minor constituent of the normal bile pool acid in man. 4 Its clinical use has become important in the treatment of cholesterol gall stones, 5 primary biliary cirrhosis, 6 and sclerosing cholangitis. 7 Oral administration of ursodeoxycholic acid makes the bile unsaturated with cholesterol because of reduced cholesterol secretion. 8,9 In contrast to treatment with chenodeoxycholic acid, the synthesis of primary bile acids is not suppressed during ursodeoxycholic acid treatment. 10 When ursodeoxycholic acid becomes the major bile acid secreted, the absorption of dietary and biliary cholesterol is reduced through the decreased micellar solubilisation power of this bile acid. 11,12 Finally, there may be competition between ursodeoxycholic acid and the other bile acids for the intestinal bile acid transport system. 13

Bile acid absorption can now be determined by using \(^{75}\)Selenium homocholic acid taurine (\(^{75}\)SeHCAT), a synthetic analogue of the natural conjugated bile acid taurocholic acid with the \( \gamma \) emitter \(^{75}\)Se in the side chain. 14 15 It has been shown in previous studies that SeHCAT behaves like the natural bile acid with regard to enterohepatic cycling, hepatic handling, active absorbtion from the terminal ileum, faecal excretion, and overall turnover in the enterohepatic circulation. 16 17 The only difference is that SeHCAT undergoes negligible deconjugation by colonic bacteria.

This investigation was undertaken to study the effect of treatment with ursodeoxycholic acid on endogenous bile acid absorption using the SeHCAT technique. A detailed study was performed simultaneously on the effects on plasma lipoprotein values and serum bile acid composition.

Methods

SUBJECTS
This study comprised eight healthy normo-lipidaemic volunteers with relative body weight <120% (Table I). All of them took 15 mg/kg/day of ursodeoxycholic acid and five of them later continued with 30 mg/kg/day. After a basal clinical and laboratory evaluation excluding heart, kidney, thyroid, liver disease, and diabetes, they were followed closely as outpatients and allowed to continue their normal diet. Informed consent was obtained from each sub-

Metabolism Unit and Division of Gastroenterology, Department of Medicine, Karolinska Institutet, Huddinge University Hospital, Huddinge, Sweden
S Eusufzai S Ericsson T Cederlund K Einarsson B Angelin

Correspondence to: Dr S Eusufzai, Department of Medicine, Huddinge University Hospital, S-141 86 Huddinge, Sweden.

Accepted for publication 16 October 1990


Table I  Basal data on the subjects

<table>
<thead>
<tr>
<th>Subject no/sex</th>
<th>Age (yrs)</th>
<th>Bodyweight (kg)</th>
<th>Relative (%)*</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/M</td>
<td>44</td>
<td>90</td>
<td>120</td>
</tr>
<tr>
<td>2/M</td>
<td>36</td>
<td>64</td>
<td>88</td>
</tr>
<tr>
<td>3/M</td>
<td>34</td>
<td>81</td>
<td>103</td>
</tr>
<tr>
<td>4/M</td>
<td>31</td>
<td>56</td>
<td>81</td>
</tr>
<tr>
<td>5/M</td>
<td>48</td>
<td>75</td>
<td>88</td>
</tr>
<tr>
<td>6/M</td>
<td>31</td>
<td>74</td>
<td>82</td>
</tr>
<tr>
<td>7/M</td>
<td>40</td>
<td>94</td>
<td>108</td>
</tr>
<tr>
<td>8/F</td>
<td>29</td>
<td>58</td>
<td>91</td>
</tr>
</tbody>
</table>

*p<0.05; **p<0.001

*Relative body weight = bodyweight (kg) × 100%

Height (cm) – 100

Object, and the ethical aspects of the study were approved by the Ethical Committee of the Karolinska Institute, Stockholm.

Experimental Procedure
Basal data obtained before the start of ursodeoxycholic acid treatment included fasting blood samples for serum lipid, lipoprotein, and bile acids concentrations.

SeHCAT (10 μCi, Amersham International) was given orally with a drink of water following the technique described by Thaysen et al. The initial count rate (100% value) was injected three hours after the intake of isotope (day 0), with the subject lying in supine and prone position under an uncollimated gamma camera (Porta Camera, General Electric. Nuclear Medical ApS, Denmark). The distance between the bed and the gamma camera crystal was maintained at 75 cm and the crystal (Na I) was centred over the middle of the xiphoidomammary line. The count rate in a 25% window centred around the 265 and 280 KeV photon peaks of 75Se was measured. The measurements, which took 10 minutes (five minutes each position), were repeated on days 2, 4, and 7 after the administration of the capsule. The background activity was subtracted and correction was made for the decay of the isotope. The geometric means of the counts measured in the anterior and posterior positions were plotted in a logarithmic-linear graph. An exponential function was fitted to the data points using the method of least squares.

The T1/2—that is the time when the abdominal retention of the SeHCAT was reduced to 50% of initial, was calculated from the curve, as well as the fractional catabolic rate defined as ln2/T1.

After completing the SeHCAT test the subjects were given ursodeoxycholic acid (Ursofalk, Dr Falk GmbH & Co, Germany, purity >99%) in a dose of 15 mg/kg/day for three weeks. Fasting blood samples (obtained 12–14 hours after intake) were then collected again, and the SeHCAT test was repeated. The treatment was continued during the studies. After completing the second SeHCAT test, five of the subjects increased the dose of ursodeoxycholic acid to 30 mg/kg/day in order to load further the bile acid transport system. Fasting blood samples were collected after one week, and the SeHCAT test was repeated during continued 'high dose' treatment.

Biochemical Analysis

Serum lipoproteins
Cholesterol and triglyceride concentrations were determined with automated enzymatic techniques (Boehringer Mannheim Test Combination Cholesterol and Triglycerides, respectively). Serum lipoprotein analysis was performed by a combination of ultracentrifugation and precipitation.

Serum bile acids
Serum together with added internal standards (1H-cholesterol, 3H-cholenoxycholic acid, 3H-deoxycholic acid, and 3H-ursodeoxycholic acid) was subjected to hydrolysis, acidification, and methylation. The methylated extracts were silylated and analysed by gas chromatography mass spectrometry with an NERMAG R10-10H Quadropole instrument equipped with a multiple ion detector unit. Details of the method have been described elsewhere.

Statistical Analysis
The results are expressed as mean (SD) values. The statistical significance of differences was evaluated by Student’s paired t test.

Results
Giving ursodeoxycholic acid at a dose of 15 mg/kg/day resulted in increased excretion of SeHCAT in all subjects (Table II). The mean fractional catabolic rate increased by 64%, from 0.203 (0.061) to 0.333 (0.159)/day (mean (SD);

Table II  Effect of treatment with ursodeoxycholic acid (UDCA) on fractional catabolic rate (FCR) (/day) and T1/2 (days) of SeHCAT

<table>
<thead>
<tr>
<th>Subject no</th>
<th>Basal FCR</th>
<th>UDCA treatment, 15 mg/kg/day FCR</th>
<th>Retention at day 7 (%)</th>
<th>T1/2</th>
<th>UDCA treatment, 30 mg/kg/day FCR</th>
<th>Retention at day 7 (%)</th>
<th>T1/2</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0.0162</td>
<td>0.27</td>
<td>32</td>
<td>0.196</td>
<td>3.53</td>
<td>25</td>
<td>2.45</td>
</tr>
<tr>
<td>2</td>
<td>0.0144</td>
<td>4.80</td>
<td>37</td>
<td>0.274</td>
<td>2.53</td>
<td>25</td>
<td>1.96</td>
</tr>
<tr>
<td>3</td>
<td>0.0183</td>
<td>3.79</td>
<td>28</td>
<td>0.328</td>
<td>2.11</td>
<td>25</td>
<td>2.02</td>
</tr>
<tr>
<td>4</td>
<td>0.0218</td>
<td>3.18</td>
<td>22</td>
<td>0.279</td>
<td>2.48</td>
<td>25</td>
<td>1.87</td>
</tr>
<tr>
<td>5</td>
<td>0.0122</td>
<td>5.68</td>
<td>43</td>
<td>0.192</td>
<td>3.61</td>
<td>27</td>
<td>4.65</td>
</tr>
<tr>
<td>6</td>
<td>0.0303</td>
<td>2.29</td>
<td>13</td>
<td>0.693</td>
<td>1.00</td>
<td>&lt;1</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>0.0242</td>
<td>2.86</td>
<td>19</td>
<td>0.358</td>
<td>1.80</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>0.0259</td>
<td>2.77</td>
<td>19</td>
<td>0.318</td>
<td>2.18</td>
<td>10</td>
<td></td>
</tr>
</tbody>
</table>

Mean (SD) (1–8)

Mean (SD) (1–8)

*p<0.05; **p<0.01; ***p<0.001 compared with basal value.
density or high density lipoprotein cholesterol during treatment at either dosage.

**Discussion**

Several distinct effects of ursodeoxycholic acid on bile acid and cholesterol metabolism in normolipidaemic humans are evident from the present study. Firstly, we could show directly a dose related interaction with the absorption of SeHCAT, indicating competitive inhibition of the intestinal uptake of this radiolabelled bile acid analogue. Since SeHCAT has very similar physiological properties to taurocholic acid, a disturbance of its reabsorption should reflect interaction with the active transport system in the terminal ileum. A tendency for an increased fractional catabolic rate of radiolabelled cholic acid during ursodeoxycholic acid treatment has also been observed during kinetic studies in humans, but the present approach should give a more sensitive detection since SeHCAT is stable and does not undergo deconjugation by colonic bacteria.

Although the molecular properties of the intestinal bile acid carrier are not yet known in detail, physiological studies have indicated that the transport system has a preference for trihydroxy bile acids and that it is working relatively close to saturation under physiological conditions. An increased load of exogenous ursodeoxycholic acid should thus preferentially interfere with the enterohepatic circulation of cholic acid. In accordance with this contention, the excretion of cholic acid was increased somewhat more than that of chenodeoxycholic acid during short term administration of ursodeoxycholic acid to patients with ileostomy. Such an exclusion of cholic acid (and chenodeoxycholic acid) from the enterohepatic circulation would result in reduced amounts of primary bile acids being returned to the liver via the portal venous circulation. Since ursodeoxycholic acid does not seem to suppress bile acid synthesis or the activity of its rate limiting enzyme, cholesterol 7α-hydroxylase, such treatment would result in an increase in bile acid production in order to maintain the pool sizes of these bile acids.

A second new finding in this study emerges from the determination of individual serum bile acid concentrations (Table III). In agreement with previous studies, the administration of 15 mg/kg/day of ursodeoxycholic acid leads to a large increase in the serum concentration of this bile acid, whereas there were no significant changes in the concentrations of cholic acid, chenodeoxycholic acid, or deoxycholic acid. This indicates that despite the increased loss of endogenous bile acid during ursodeoxycholic acid therapy, the pool sizes of these bile acids were maintained. This concept could now be extended to treatment with large amounts of ursodeoxycholic acid (30 mg/kg/day), where still no changes in serum bile acid concentrations could be observed, despite a more than 40 fold increase in ursodeoxycholic acid serum concentrations. It should be noted that all these measurements refer to the fasting state, and that a reduced return of bile acids may be present postprandially, as has recently been shown.
Effect of ursodeoxycholic acid treatment on ileal absorption of bile acids in man as determined by the SeHCAT test

This work was presented at the Second International Meeting on Pathochemistry, Pathophysiology, and Pathomechanics of the Biliary System and New Strategies for the Treatment of Hepato-biliary Diseases, Bologna, Italy, March 1990.


27 Albers JJ, Grundy SM, Cleary PA, Small DM, Lachin JM, Schoenberg LJ, and the National Cooperative Gallstone...
Eusufzai, Ericsson, Cederlund, Einarsson, Angelin


Effect of ursodeoxycholic acid treatment on ileal absorption of bile acids in man as determined by the SeHCAT test.

S Eusufzai, S Ericsson, T Cederlund, K Einarsson and B Angelin

_gut_ 1991 32: 1044-1048
doi: 10.1136/gut.32.9.1044

Updated information and services can be found at:
http://gut.bmj.com/content/32/9/1044

These include:

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/